Pancreatic cancer

Active Research Protocols

  1. 07-C-0111 – A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies
  2. 08-H-0186 – Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK√?TRAIL Cytotoxicity with Bortezomib
  3. 11-C-0099 – Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
  4. 11-C-0140 – A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
  5. 11-C-0212 – A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin over Expressing Cancers
  6. 11-C-0267 – A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Adminstration of GVAX Pancreas Vaccine (with Cyclophosphamide) Alone or Followed by CRS-207 in Adults with Metastatic Pancreatic Adenocarcinoma
  7. 12-C-0008 – An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Antimesothelin Antibody Drug Conjugate BAY 94-9343 in Subjects with Advanced Solid Tumors
  8. 12-C-0111 – Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes
  9. 12-C-0175 – Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
  10. 13-C-0009 – A Multicenter Phase I/IIB Study of NPC-1C in Combination with Gemcitabine in Patients with Metastatic or Locally Advanced Pancreatic Cancer Previously Treated with FOLFIRINOX
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014